Zai Lab Ltd.

While significant progress has been made in the treatment of non-small cell lung cancer (NSCLC), small-cell lung cancer (SCLC) has seen fewer advances and patients continue to have limited treatment o

In a marked departure from its established business model of in-licensing external assets, Zai Lab is now pulling off a crossover into the self-discovery of first-in-class molecules. The biopharma com

China’s retaliatory tariffs mean the option of manufacturing US-originated drugs in China is making more sense than ever, at least to some local partners of US pharmaceutical companies. China imposed

Taiho Pharmaceuticals said on 17 March that it will spend $400m up front and up to $740m in milestone payments to expand its cancer drug development pipeline through the acquisition of antibody-drug c